Navigation Links
Management in Medical Technology

Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease

CLEVELAND, July 28 /PRNewswire/ -- More than 340,000(2) women suffer from postmenopausal osteoporosis (PMO) in Ohio and more than 900,000(3) are at risk for the disease. According to a census report on the prevalence of osteoporosis, the number of women suffering from the...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patie...

Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder

ROCHESTER, Minn., Feb. 11 /PRNewswire-USNewswire/ -- In a study published in The American Journal of Psychiatry , a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for th...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced changes to conserve the Company's resources, focus its efforts on its late-stage obesity programs and realign its management team. The key aspects of these changes are as follows: ...

Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin

SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, announced today that it will be exploring strategic alternatives for its preclinical research programs in order to a...

Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution

BOSTON, Oct. 15 /PRNewswire-FirstCall/ -- Perceptive Informatics, one of the industry's leading eClinical technology providers and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL ), announced today that it has enhanced its TrialWorks(R) solution, a specialized Clinical Trial M...

Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)

FORT WORTH, Texas, Sept. 30 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it will attend and exhibit at the Wound Care Seminar: Clinical and Economical Realities in Boston. This semin...

Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team

MONTREAL, Sept. 22 /PRNewswire/ -- Enobia Pharma, a biotech company focused on developing novel therapeutics for serious bone disorders, today announced key appointments to add commercial and manufacturing expertise to the Company's senior management team in conjunction with the recent initiat...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from its Phase III pivotal efficacy trial that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochl...

Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO ), a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new dru...

Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company

Company Focuses Operations, Updates Zingo Launch Progress and Adlea Registration Strategy Conference Call Today at 11:30 am ET SOUTH SAN FRANCISCO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) announced today that the compa...

Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders

CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- As biotechnology, pharmaceutical and medical device companies increasingly move clinical trials beyond their own borders to other parts of the world, such as Asia, Eastern Europe and South America, complicated regulatory environments challenge those f...

Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain

ASHBURN, Va., Aug. 8 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) B...

Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers

FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen ...

New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)

BETHLEHEM, Pa., June 23 /PRNewswire/ -- A new blood test may make it easier for oncologists to accurately measure and personalize 5-fluorouracil (5-FU) dosing for patients undergoing continuous infusion chemotherapy regimens. Data from a multicenter trial showed that a nanoparticle-based immun...

Saladax Biomedical's 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU

BETHLEHEM, Pa., June 17 /PRNewswire/ -- Saladax Biomedical, a company specializing in chemotherapy therapeutic drug monitoring, today announced CE mark registration in the European Union (EU) for its 5-FU Personalized Chemotherapy Management (PCM(R)) assay on the Olympus AU400 Clinical Chemist...

Wound Management Technologies, Inc. Announces Evidence Based Study

FORT WORTH, Texas, June 3 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc. (formerly MB Software Corporation (OTC Bulletin Board: MBSB)) announced today that it will begin an evidence based study evaluating the clinical performance of t...

University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients

New data presented at annual American Transplant Congress in Toronto MIAMI, June 2 /PRNewswire/ -- Manuel R. Carreno, MD, and colleagues in the Departments of Surgery and Pathology at the University of Miami - Lawrence Miller School of Medicine have corroborated the value of monitoring cell-...

Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer

BETHLEHEM, Pa., May 2 /PRNewswire/ -- Can a blood test improve treatment outcomes for colorectal cancer patients? Recently published studies indicate that personalized chemotherapy dose management -- measuring drug levels in patients' blood and adjusting them for optimal dosing -- can substant...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain

ASHBURN, Va., Jan. 4 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IM...

Micromet Announces Changes in Management Team

BETHESDA, Md., Dec. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the resignation of Christopher...

Lilly Receives NCQA Design Certification for Depression Care Management Program

INDIANAPOLIS, Nov. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) has received Program Design Certification from the National Committee for Quality Assurance (NCQA) for its Tools that Empower(TM) Depression Care Management Program. Tools that Empower(TM) Depression Care Manag...

New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo

Interim Results From Open-Label Follow-up Include Longer-term Safety Findings BOSTON, Oct. 26 /PRNewswire/ -- Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA(R) OROS(R) methylphenidate HCl Extended-release Tablets showed signif...

Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels

BOULDER, Colo., Oct. 22 /PRNewswire/ -- Sciona, Inc., a leader in the science of nutrigenetics, today announced the results of a pivotal study published by Nutrition Journal, which demonstrates substantial advances in long term weight management and blood glucose levels as a result of personal...

Cellectar Expands Clinical Management Team

- Appoints Director, Clinical Operations and Manager, Medical Affairs - MADISON, Wis., Oct. 3 /PRNewswire/ -- Cellectar LLC, (Cellectar), a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment...

Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting

NKTR-118 Currently in Phase 1 Clinical Development for the Treatment of Opioid Bowel Dysfunction SAN CARLOS, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented positive results this week from Phase 1 and preclinical studies of NKTR-...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has hired industry veterans Eric D. Malek as vice president of corporate development and Deborah A. Thomas as vice president fo...

New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

TRILIPIX has now been studied in combination with the most commonly used doses of rosuvastatin calcium (5 mg, 10 mg, 20 mg) in patients with mixed dyslipidemia ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Data from a new study showed that Abbott 's TRILIPIX(R) (fenofibric acid) delayed-...

Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management

Renowned cancer research center enters into a Technology Transition agreement with OmniComm to gain more control over the management of their clinical trials FT. LAUDERDALE, Fla., Nov. 4 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB...

U.S. Preventive Medicine Acquires Specialty Disease Management

DALLAS, Oct. 2 /PRNewswire/ -- U.S. Preventive Medicine(R) (http://www.USPreventiveMedicine.com ) a company organizing and commercializing the market for proactive preventive health services, announced today the acquisition of Specialty Disease Management Services, Inc., a national provider o...

The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management

WESTBURY, N.Y., Aug. 25 /PRNewswire/ -- "Weight management is serious business. National health authorities are concerned that more than half of Americans are over weight, and for many obesity is not merely a matter of looking unattractive. It is a health hazard. Then why leave it to amateurs ...

Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management

CHAPEL HILL, N.C., Aug. 10 /PRNewswire/ -- More than 33% of pharmaceutical and biotech companies are able to identify clinical investigators 50% faster than their industry peers. These companies are able to significantly reduce clinical trial costs while improving quality by employing on-going...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligence firm La Merie S.L. reported today that Sanofi-Aventis’ first-in-class CB1 ...

Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference

PETALUMA, Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today reported that its Microcyn Technology was the subject of a poster presentation at the European Wound Management Association (EWMA) conference that was held in Glasgow, Scotland this past week. Th...

Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001

HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeutic vaccine developed by the German company VPM to battle prostate cancer promises new hope for cancer patients. The results of a successfully completed clinical study will be presented to an international audience at the Annual Conference ...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation Sciences, Inc. (T.A. Sciences) recently announced the results of the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial ever to show demonstrated, measurable and positive anti-aging benefits from a Telomerase Activator. Stati...

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its...

Choosing Lab Quality Management Software

Summary Lakeridge Healths large multi-site lab faced challenges with manual document control processes and accreditation management challenges which were exacerbated by staff shortages and growing test volumes. The lab realized that better document control was essential for accreditation ...

Optimizing Quality Control Data Management

Introduction Automation continues to gain importance in modern clinical laboratories in step with increasing test consolidation, rising demands from clinicians for rapid turnaround times, and an ever-mounting shortage of licensed medical technologists. Ultimately, the laboratories that implem...
Other Tags
(Date:4/14/2014)... face the decision of whether to get a ... decision can be even more challenging. Now, a ... decisions in families of children with autism and ... parents reported the benefits of dog ownership included ... to learn responsibility. , "Children with autism spectrum ...
(Date:4/14/2014)... plant growth chamber bound for the International Space ... resupply mission may help expand in-orbit food production ... astronauts something they don,t take for granted, fresh ... to study the in-orbit function and performance of ... and its plant "pillows." The investigation will focus ...
(Date:4/14/2014)... sponges sound like creatures from a B-grade horror movie. ... the deep sea. Scientists first discovered that some sponges ... seven carnivorous species have been found in all of ... marine biologist Lonny Lundsten and two Canadian researchers describes ... deep seafloor, from the Pacific Northwest to Baja California. ...
Breaking Biology News(10 mins):Dog ownership benefits families of children with autism, MU researcher finds 2Veggie will expand fresh food production on space station 2Researchers describe 4 new species of 'killer sponges' from the deep sea 2Researchers describe 4 new species of 'killer sponges' from the deep sea 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
Other Contents